Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).

Nicholas David James; Sarah Pirrie; Darren Barton; Janet Elizabeth Brown; Lucinda Billingham; Stuart I. Collins; Adam Daunton; Alison J. Birtle; Prabir Ranjan Chakraborti; Daniel Ford; Syed A. Hussain; Helen Jones; Ann Pope; Emilio Porfiri; John Martin Russell; Andrew Stanley; John Staffurth; Duncan McLaren; Chris Parker; James Wylie

Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).

Nicholas David James, Sarah Pirrie, Darren Barton, Janet Elizabeth Brown, Lucinda Billingham, Stuart I. Collins, Adam Daunton, Alison J. Birtle, Prabir Ranjan Chakraborti, Daniel Ford, Syed A. Hussain, Helen Jones, Ann Pope, Emilio Porfiri, John Martin Russell, Andrew Stanley, John Staffurth, Duncan McLaren, Chris Parker, James Wylie

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	31
Issue number	18
Publication status	Published - 20 Jun 2013
Event	49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, Israel Duration: 31 May 2013 → 4 Jun 2013

Cite this

James, N. D., Pirrie, S., Barton, D., Brown, J. E., Billingham, L., Collins, S. I., Daunton, A., Birtle, A. J., Chakraborti, P. R., Ford, D., Hussain, S. A., Jones, H., Pope, A., Porfiri, E., Russell, J. M., Stanley, A., Staffurth, J., McLaren, D., Parker, C., & Wylie, J. (2013). Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). Journal of Clinical Oncology, 31(18).

@article{56da5243c78a477d82c7ad84a85961c0,

title = "Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).",

author = "James, {Nicholas David} and Sarah Pirrie and Darren Barton and Brown, {Janet Elizabeth} and Lucinda Billingham and Collins, {Stuart I.} and Adam Daunton and Birtle, {Alison J.} and Chakraborti, {Prabir Ranjan} and Daniel Ford and Hussain, {Syed A.} and Helen Jones and Ann Pope and Emilio Porfiri and Russell, {John Martin} and Andrew Stanley and John Staffurth and Duncan McLaren and Chris Parker and James Wylie",

year = "2013",

month = jun,

day = "20",

language = "English",

volume = "31",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "18",

note = "49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) ; Conference date: 31-05-2013 Through 04-06-2013",

}

James, ND, Pirrie, S, Barton, D, Brown, JE, Billingham, L, Collins, SI, Daunton, A, Birtle, AJ, Chakraborti, PR, Ford, D, Hussain, SA, Jones, H, Pope, A, Porfiri, E, Russell, JM, Stanley, A, Staffurth, J, McLaren, D, Parker, C & Wylie, J 2013, 'Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).', Journal of Clinical Oncology, vol. 31, no. 18.

Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). / James, Nicholas David; Pirrie, Sarah; Barton, Darren et al.
In: Journal of Clinical Oncology, Vol. 31, No. 18, 20.06.2013.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).

AU - James, Nicholas David

AU - Pirrie, Sarah

AU - Barton, Darren

AU - Brown, Janet Elizabeth

AU - Billingham, Lucinda

AU - Collins, Stuart I.

AU - Daunton, Adam

AU - Birtle, Alison J.

AU - Chakraborti, Prabir Ranjan

AU - Ford, Daniel

AU - Hussain, Syed A.

AU - Jones, Helen

AU - Pope, Ann

AU - Porfiri, Emilio

AU - Russell, John Martin

AU - Stanley, Andrew

AU - Staffurth, John

AU - McLaren, Duncan

AU - Parker, Chris

AU - Wylie, James

PY - 2013/6/20

Y1 - 2013/6/20

M3 - Meeting abstract

SN - 0732-183X

VL - 31

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 18

T2 - 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Y2 - 31 May 2013 through 4 June 2013

ER -